Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Biol Chem ; 280(13): 12523-35, 2005 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-15613471

RESUMEN

Presenilins appear to form the active center of gamma-secretase but require the presence of the integral membrane proteins nicastrin, anterior pharynx defective 1, and presenilin enhancer 2 for catalytic function. We have simultaneously overexpressed all of these polypeptides, and we demonstrate functional assembly of the enzyme complex, a substantial increase in enzyme activity, and binding of all components to a transition state analogue gamma-secretase inhibitor. Co-localization of all components can be observed in the Golgi compartment, and further trafficking of the individual constituents seems to be dependent on functional assembly. Apart from its catalytic function, gamma-secretase appears to play a role in the trafficking of the beta-amyloid precursor protein, which was changed upon reconstitution of the enzyme but unaffected by pharmacological inhibition. Because the relative molecular mass and stoichiometry of the active enzyme complex remain elusive, we performed size exclusion chromatography of solubilized gamma-secretase, which yielded evidence of a tetrameric form of the complex, yet almost completely abolished enzyme activity. Gamma-secretase activity was reconstituted upon addition of an independent size exclusion chromatography fraction of lower molecular mass and nonproteinaceous nature, which could be replaced by a brain lipid extract. The same treatment was able to restore enzyme activity after immunoaffinity purification of the gamma-secretase complex, demonstrating that lipids play a key role in preserving the catalytic activity of this protease. Furthermore, these data show that it is important to discriminate between intact, inactive gamma-secretase complexes and the active form of the enzyme, indicating the care that must be taken in the study of gamma-secretase.


Asunto(s)
Endopeptidasas/biosíntesis , Metabolismo de los Lípidos , Glicoproteínas de Membrana/metabolismo , Péptido Hidrolasas/metabolismo , Secretasas de la Proteína Precursora del Amiloide , Precursor de Proteína beta-Amiloide/metabolismo , Ácido Aspártico Endopeptidasas , Sitios de Unión , Western Blotting , Encéfalo/metabolismo , Catálisis , Línea Celular , Membrana Celular/metabolismo , Sistema Libre de Células/metabolismo , Cromatografía , Medios de Cultivo/metabolismo , Medios de Cultivo Condicionados/farmacología , ADN Complementario/metabolismo , Dimerización , Endopeptidasas/metabolismo , Aparato de Golgi/metabolismo , Humanos , Inmunohistoquímica , Péptidos/química , Estructura Terciaria de Proteína , Factores de Tiempo
2.
J Neurochem ; 90(6): 1312-20, 2004 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-15341515

RESUMEN

Gamma-secretase performs the final processing step in the generation of amyloid-beta (Abeta) peptides, which are believed to be causative for Alzheimer's disease. Presenilins (PS) are required for gamma-secretase activity and the presence of two essential intramembranous aspartates (D257 and D385) has implicated this region as the putative catalytic centre of an aspartyl protease. The presence of several key hydrogen-bonding residues around the active site of classical aspartyl proteases led us to investigate the role of both the critical aspartates and two nearby conserved hydrogen bond donors in PS1. Generation of cell lines stably overexpressing the D257E, D385E, Y256F and Y389F engineered mutations has enabled us to determine their role in enzyme catalysis and binding of a transition state analogue gamma-secretase inhibitor. Here we report that replacement of either tyrosine residue alters gamma-secretase cleavage specificity, resulting in an increase in the production of the more pathogenic Abeta42 peptide in both cells and membranous enzyme preparations, without affecting inhibitor binding. In contrast, replacement of either of the aspartate residues precludes inhibitor binding in addition to inactivation of the enzyme. Together, these data further incriminate the region around the intramembranous aspartates as the active site of the enzyme, targeted by transition state analogue inhibitors, and highlight the roles of individual residues.


Asunto(s)
Ácido Aspártico/metabolismo , Secuencia Conservada/fisiología , Endopeptidasas/metabolismo , Activación Enzimática/fisiología , Mutagénesis Sitio-Dirigida/fisiología , Secretasas de la Proteína Precursora del Amiloide , Péptidos beta-Amiloides , Precursor de Proteína beta-Amiloide/metabolismo , Ácido Aspártico/química , Ácido Aspártico/genética , Ácido Aspártico Endopeptidasas/farmacología , Sitios de Unión/efectos de los fármacos , Sitios de Unión/fisiología , Western Blotting/métodos , Línea Celular , Membrana Celular/efectos de los fármacos , Membrana Celular/metabolismo , Sistema Libre de Células , Ácidos Cólicos/farmacología , Proteínas Cromosómicas no Histona/química , Proteínas Cromosómicas no Histona/metabolismo , Medios de Cultivo Condicionados/análisis , Detergentes/farmacología , Embrión de Mamíferos , Endopeptidasas/química , Endopeptidasas/genética , Activación Enzimática/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Humanos , Riñón , Fragmentos de Péptidos , Unión Proteica/fisiología , Pliegue de Proteína , Estructura Terciaria de Proteína , Especificidad por Sustrato , Transfección , Tirosina/química , Tirosina/genética , Tirosina/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA